R&D – Talk Bio

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

2 days ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment

Sanofi Commits $20 Billion to U.S. R&D and Manufacturing by 2030

3 weeks ago talkbio0Tagged domestic partnerships, drug launches, Investments, Manufacturing, R&D, sanofi, Surgical construction, United States

Sanofi; $20 billion investment; U.S. manufacturing; R&D; job creation; drug launches; domestic partnerships

Sanofi Commits $20 Billion to US Expansion Amid Industry-Wide Investment Surge

3 weeks ago talkbio0Tagged drug production, Industry, Investments, pharmaceutical manufacturing, R&D, sanofi, supply chain, Surgical construction, trends qualifier, U.S.

Sanofi; US investment; pharmaceutical manufacturing; R&D; drug production; job creation; supply chain; industry trends

Gilead tees up $11B in new US manufacturing, R&D investments

1 month ago talkbio0Tagged Billion, Investments, Manufacture, R&D, U.S., United States

United States, Investments, Manufacture, R&D, Billion, U.S.

Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase

1 month ago talkbio0Tagged 8, Biological Factors, Financial cost, Financial savings, generics, Investments, Operational streamlining, Pivot Device, R&D, Strategic Overhaul, Workforce reduction

Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment

AstraZeneca’s China woes recede as focus shifts to upcoming readouts

1 month ago talkbio0Tagged Acquisition, Beijing, biotech, China, China legal issues resolution, FibroGen, Fine - adjective, global strategic R&D center, Investments, Manufacturing, partnerships, R&D

$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition